🇺🇸 FDA
Pipeline program

Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

WO39613

Phase 1 small_molecule active

Quick answer

Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE for Urothelial carcinoma (UC) is a Phase 1 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

Program details

Company
Hoffmann-La Roche
Indication
Urothelial carcinoma (UC)
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials